During the past decade, Swedish Neuroscience Institute; Multiple Sclerosis Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Swedish Neuroscience Institute; Multiple Sclerosis Center" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Acorda Therapeutics" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Genzyme, a Sanofi Company" with 1 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Swedish Neuroscience Institute; Multiple Sclerosis Center" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Immune Tolerance Network (ITN)" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Swedish Neuroscience Institute; Multiple Sclerosis Center" are "Multiple Sclerosis" (2 trials), "Relapsing Remitting Multiple Sclerosis" (2 trials), "Multiple Sclerosis (MS)" (1 trials), "Multiple Sclerosis, Primary Progressive" (1 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "Swedish Neuroscience Institute; Multiple Sclerosis Center" in a lesser frequency.

Most popular intervention types in "Swedish Neuroscience Institute; Multiple Sclerosis Center" are "Drug" (4 trials), "Biological" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (3 trials), "Placebo" (2 trials), "10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)" (1 trials), "15 mg fampridine-SR (4-aminopyridine, 4-AP)" (1 trials) and "20 mg fampridine-SR (4-aminopyridine, 4-AP)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Swedish Neuroscience Institute; Multiple Sclerosis Center" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Swedish Neuroscience Institute; Multiple Sclerosis Center". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Swedish Neuroscience Institute; Multiple Sclerosis Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Swedish Neuroscience Institute; Multiple Sclerosis Center, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".